Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of European Generic Clopidogrel vs US and Japanese Plavix
NCT02185534Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clopidogrel in atherothrombosis (3 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve From Time Zero Extrapolated to Infinity at 36 hours and Observed Maximum Plasma Concentration at 36 hours. Started Aug 2014; status: completed.
02
Drugs
clopidogrel
03
Conditions
atherothrombosis
Beyond the preview
Go deeper on NCT02185534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185534.